Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
You may also be interested in...
To date, nine major pairs of antibody and payload-linker platform makers based in China are making a concerted approach for ADC research and development, research by Scrip reveals.
Keytruda brought in its usual stacks of cash, but Merck’s Q3 earnings call focused largely on a recent alliance with Daiichi Sankyo and the pharma’s growing emphasis on cancer ADCs.
Merck & Co's antibody-drug conjugates pact with Kelun is progressing well and the lead candidate of the pact, the TROP2-targeting candidate codenamed SKB264/MK-2870, has significantly improved progression-free survival in triple-negative breast cancer patients in a late-stage trial in China.